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Abstract: Background: Staging of atrial fibrillation (AF) is essential to understanding disease
progression and the accompanied increase in therapy failure. Blood-based heat shock protein
(HSP) levels may enable staging of AF and the identification of patients with higher risk for AF
recurrence after treatment. Objective: This study evaluates the relationship between serum HSP
levels, presence of AF, AF stage and AF recurrence following electrocardioversion (ECV) or pulmonary
vein isolation (PVI). Methods: To determine HSP27, HSP70, cardiovascular (cv)HSP and HSP60
levels, serum samples were collected from control patients without AF and patients with paroxysmal
atrial fibrillation (PAF), persistent (PeAF) and longstanding persistent (LSPeAF) AF, presenting for
ECV or PVI, prior to intervention and at 3-, 6- and 12-months post-PVI. Results: The study population
(n = 297) consisted of 98 control and 199 AF patients admitted for ECV (n = 98) or PVI (n = 101).
HSP27, HSP70, cvHSP and HSP60 serum levels did not differ between patients without or with
PAF, PeAF or LSPeAF. Additionally, baseline HSP levels did not correlate with AF recurrence after
ECV or PVI. However, in AF patients with AF recurrence, HSP27 levels were significantly elevated
post-PVI relative to baseline, compared to patients without recurrence. Conclusions: No association
was observed between baseline HSP levels and the presence of AF, AF stage or AF recurrence.
However, HSP27 levels were increased in serum samples of patients with AF recurrence within one
year after PVI, suggesting that HSP27 levels may predict recurrence of AF after ablative therapy.
Keywords: atrial fibrillation; heat shock protein; electrical cardioversion; pulmonary vein
isolation; biomarkers
1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with a rising prevalence due to
the aging population [1]. Proper staging of AF is essential to select the optimal treatment strategies
to prevent AF progression, and the accompanied risk to develop severe complications such as
thromboembolic events, heart failure, cognitive impairment and increased mortality [2,3]. At present,
AF can only be diagnosed with a surface electrocardiogram when a patient already suffers from AF,
Cells 2020, 9, 2105; doi:10.3390/cells9092105 www.mdpi.com/journal/cells
Cells 2020, 9, 2105 2 of 12
presenting with palpitations or thromboembolic complications. However, diagnosis of AF may be
challenging in patients with asymptomatic or very short-lasting episodes of AF [4]. In addition,
treatment aimed at rhythm control, such as ablative therapy, is less successful in patients with
persistent AF, compared to paroxysmal AF [3]. Hence, proper staging of AF and the start of effective
treatment of AF is of utmost importance. Therefore, there is an urgent need to identify diagnostic
biomarkers to stage AF and guide patient-tailored therapy [5].
Biomarkers are widely accepted as a diagnostic tool to screen or monitor patients for a variety of
cardiovascular diseases. At present, there are no recommendations on the use of AF-specific biomarkers
in the most recent guidelines [3,6], despite the fact that several blood-based biomarkers related to AF
pathology have been identified. These biomarkers include brain natriuretic peptides, cancer-antigen-125,
fibroblast growth factor-23 [7,8] and -21 [9], highly sensitive cardiac troponin I [10], homocysteine [11],
(a)symmetric dimetylarginine [12], interleukine-6 and matrix metalloproteinase-9/tissue inhibitor of
metalloproteinase-1 ratio [13]. Although potential AF-related biomarkers are available, the role of these
biomarkers in staging of AF (paroxysmal or (longstanding) persistent AF) or predicting AF recurrence
after AF therapy has only be moderately studied.
Emerging evidence indicates that heat shock proteins (HSPs) may represent a suitable biomarker to
predict AF recurrence after treatment. HSPs are chaperones that play an important role in safeguarding
proteostasis, the homeostasis of protein expression, and function and degradation in cells [14].
The derailment of proteostasis has been identified as a key factor underlying electropathology and
AF progression [14–16]. During stress or disease, such as AF, especially, activation of the heat shock
transcription factor 1 regulates HSP transcription [17]. Within the HSP family, small HSPs, including
HSP27, are probably the most important in maintaining proteostasis in cardiomyocytes by stabilizing
the contractile proteins [18–21]. Previously, atrial HSP27 levels were found to be induced in atrial
tissue samples of patients with paroxysmal AF, while tissue HSP27 levels get exhausted in patients
with (longstanding) persistent AF [18], indicating that low tissue HSP levels are associated with AF
progression. The study of Hu et al. described that low baseline serum HSP27 levels of patients who
received ablative therapy predict AF recurrence and patients with high baseline serum levels of HSP27
showed an improved maintenance rate of sinus rhythm [22]. So far, it is unknown which HSP family
member(s) represent biomarkers to identify the stage of AF and recurrence after therapy. In the current
study, various members of the HSP family, including HSP27, HSP70, cardiovascular (cv)HSP and
HSP60, were measured in serum samples of control and patients with paroxysmal atrial fibrillation
(PAF), persistent atrial fibrillation (PeAF) and longstanding persistent atrial fibrillation (LSPeAF),
undergoing elective electrical cardioversion (ECV) or pulmonary vein isolation (PVI), to identify
whether HSPs associate with the stage of AF and recurrences after either PVI or ECV. Herein, we report
that baseline HSP levels between control and AF patients are comparable. However, HSP27 levels were
increased in follow-up samples of patients with AF recurrence after PVI, suggesting that increased
HSP27 levels may predict recurrence of AF after ablative therapy.
2. Materials and Methods
2.1. Study Popultion
From December 2014 till November 2016, 297 subjects >18 years with or without a history of AF
were prospectively enrolled for the HALT & REVERSE study [23] at the department of cardiology
in the Erasmus MC, Rotterdam, the Netherlands. The study population consists of a control group
of patients without a history of AF and a study group of patients with symptomatic AF who were
scheduled for electrical cardioversion (ECV) or pulmonary vein isolation (PVI).
The control group consisted of patients (n = 98) who were scheduled for elective ablation of
premature ventricular contractions (PVC), Wolff–Parkinson–White syndrome (WPW) or Ajmaline
testing. These patients were eligible for inclusion in case of absence of structural heart disease and any
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atrial tachyarrhythmia. Blood serum samples were obtained 1 day prior to the scheduled intervention.
Follow-up was not performed.
The study group included patients presenting for ECV (n = 98) or PVI (n = 101) for either
symptomatic PAF (less than 7 days of AF), PeAF (having AF between 7 days and 1 year) or LSPeAF
(more than 1 year of AF). Exclusion criteria included paced atrial rhythms, cancer, inflammation and
rheumatic diseases. Blood samples were obtained 1 day prior to the scheduled intervention. PVI was
unsuccessful in two patients.
Patients who underwent PVI visited the outpatient clinic at 3-, 6- and 12-months after the
procedure to provide follow-up serum samples and to screen for AF recurrences. Due to rescheduling
of patients to different hospitals, follow-up serum samples were not available for some patients in
both the AF recurrence and no recurrence group. In addition, AF recurrence data is available via
recordings of inbetween visits due to AF complaints of the patients. AF recurrence was defined as an
AF episode documented on either a 12-lead surface ECG or Holter monitor recordings. In patients
undergoing ECV, for each individual patient only 3-, 6- and 12-months post-procedural follow-up
telephone consultations were scheduled. The study endpoint was the completion of the 12-months
follow-up period or earlier due to withdrawn informed consent, pacemaker implant or AF recurrence.
Clinical characteristics were obtained from the electronic patients’ files.
All patients signed written informed consent prior to inclusion. This sub-study is part of the HALT
AND REVERSE trial (MEC-2014-393), and is approved by the institutional medical ethical committee.
The study is carried out according to the principals of the Declaration of Helsinki in accordance with
the Medical Research Committee involving the Human Subjects Act.
2.2. HSP Measurement in Serum Samples
Immediately after blood sample collection, serum was harvested from blood in BD Vacutainer™ SST™
II Advance Tubes (Fisher Scientific, Bleiswijk, the Netherlands) by centrifugation at 2000× g for 10 min at
4 ◦C and frozen in −80 ◦C until analysis of HSP27, HSP70, cvHSP and HSP60 levels. For measurement
of serum HSP27 levels, samples were diluted six times, and for HSP70 levels samples were diluted
twice in 1% BSA in PBS. The amount of HSP27 and HSP70 protein was detected in triplicates using
human HSP27 or HSP70 DuoSet® ELISA kits from R&D (Cat. no. DY1580 and DY1663, respectively,
Minneapolis, MN, USA) according to the manufacturer’s instructions with minor adjustments (serum
was incubated at 4 ◦C overnight, instead of 2 h at room temperature). Undiluted serum was used to
measure cvHSP protein (singular) with ELISA kits from Cusabio (CSB-EL010838HU, Houston, TX, USA),
according to manufacturer’s instructions with minor adjustments (kept incubation temperature at 20 ◦C).
Undiluted serum was used to measure HSP60 protein in duplicate with the HSP60 DuoSet® ELISA kit
from R&D (DYC1800), according to manufacturer’s instructions.
2.3. Statistical Analysis
Data were analyzed with SPSS Statistics version 26.0 for Windows (SPSS, Inc., Chicago, IL, USA)
and GraphPad Prism version 8.0 (Graphpad Software Inc., San Diego, CA, USA). All data were tested
for Gaussian distribution. Continuous and normally distributed data are presented as mean ± standard
deviation (SD), non-normally distributed data as median [interquartile range (IQR)], and categorical
data as number (percentage). Differences in clinical characteristics and HSP levels between patients
with and without AF were tested with independent-samples t-test, Mann–Whitney and Chi-square test.
Differences in clinical characteristics and HSP levels between patients without a history of AF, PAF, PeAF
and LSPeAF were tested with one-way analysis of variance (ANOVA), Kruskal–Wallis test, Chi-square
test and Fisher’s Exact test. When serum HSP levels were below detection limit of the ELISA (only for
n = 7 cvHSP and n = 41 HSP60 samples), values at the lower limit of detection were used for statistical
analysis. HSP levels are not normally distributed and are Log-transformed for statistical analysis
(original HSP values are presented in Tables and Figures). Uni- and multivariate linear regression
was used to correlate baseline serum HSP levels with clinical parameters, and bivariate spearman
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correlation was used to correlate AF recurrence with clinical parameters. The difference between
baseline and follow-up serum HSP levels was calculated with a repeated measures model. To relate
HSP levels over time with AF recurrence and to analyze the sensitivity of the results, sensitivity analysis
was performed using joint modeling. Hereto, the occurrence of the first AF recurrence (endpoint) in
relation to the standardized (‘Z’) value of log2(HSP) was modeled, while using all measurements up to
and including the moment of the first AF recurrence in endpoint event cases, and all measurements in
those who remained event-free. A two-sided p value of < 0.05 indicates statistical significance.
3. Results
3.1. Study Population
The entire study population consisted of 297 patients (67% males, age 56.7 ± 13.4 years), including
a control group of 98 patients without AF and a study group of 199 patients with either PAF (n = 86,
29%), PeAF (n = 108, 36.4%) or LSPeAF (n = 5, 1.7%) AF. Table 1 outlines baseline characteristics of the
entire study population. Patients with AF were older (p < 0.001), more often male (p < 0.001), had a
higher BMI (p < 0.001), more often had hypertension (p < 0.001), more often had diabetes mellitus
(p < 0.001) and more often had dyslipidemia (p < 0.05), compared to patients without AF (Table 1).
Clinical parameters did not differ between patients with paroxysmal and persistent AF, except for an
impaired LVF (p < 0.001) and larger left atrial volume (p < 0.001) in the persistent AF patients.
Table 1. Clinical characteristics of the study population.
Control PAF PeAF LSPeAF All AF Patients
n (%) 98 (33) 86 (29) 108 (36.4) 5 (1.7) 199 (67)
Group, n (%)
Control 98 (100) - - - -
Electro cardioversion (ECV) - 12 (14) 83 (76.9) 3 (60) 98 (49)
Pulmonary vein isolation (PVI) - 74 (86) 25 (23.1) 2 (40) 101 (51)
Age (years), mean ± SD 48.2 ± 15.3 61.3 ± 9.5 *** 60.8 ± 10.6 *** 57.5 ± 9 60.9 ± 10.1 ***
Gender, male, n (%) 51 (52) 64 (74.4) ** 81 (75) ** 4 (80) 149 (74.9) ***
BMI (kg/m2), mean ± SD 25.1 ± 3.7 27.2 ± 3.8 * 28.8 ± 5.4 *** 30.4 ± 7.4 28.2 ± 4.9 ***
Hypertension, yes, n (%) 23 (23.5) 43 (50) *** 51 (47.2) ** 3 (60) 97 (48.7) ***
Diabetes mellitus, yes, n (%) 5 (5.1) 10 (11.6) 15 (13.9) 1 (20) 26 (13.1) *
Dyslipidemia, yes, n (%) 16 (16.3) 25 (29.1) 33 (30.6) 3 (60) 61 (30.7) **
Thyroid disease, yes, n (%) 2 (2) 4 (4.7) 8 (7.4) 1 (20) 13 (6.5)
Left ventricular function (LVF), n (%) */###
Normal 61 (79.2) 73 (84.9) 60 (58.3) 3 (60) 136 (70.1)
Mild impairment 10 (13) 9 (10.5) 29 (28.2) 2 (40) 40 (20.6)
Moderate impairment 3 (3.9) 3 (3.5) 10 (9.7) 0 (0) 13 (6.7)
Severe impairment 3 (3.9) 1 (1.2) 4 (3.9) 0 (0) 5 (2.9)
Missing † 21 0 5 0 5
Left atrial volume index
(mL/m2),median [IQR]
27.9
[21.2–39.7]
38.6
[29.3–48.4] *
47
[35.7–60.5] **/##
43.1
[25.9–73.6]
41.1
[31.8–54] **
Drugs, yes, n (%)
Drugs total 52 (53.6) 84 (97.7) *** 104 (96.3) *** 5 (100) 193 (97) ***
ACE. ARB. AT2 antagonist 26 (26.8) 40 (46.5) * 48 (44.9) * 3 (60) 91 (46) **
Statin 17 (17.5) 32 (37.2) * 37 (34.3) * 4 (80) * 73 (36.7) ***
Antiarrhythmic drugs (AAD) total ‡ 43 (44.3) 79 (91.9) *** 103 (95.4) *** 5 (100) 187 (94) ***
Class I AAD 5 (5.2) 31 (36.0) *** 14 (13) ### 1 (20) 46 (23.1) ***
Class II AAD 31 (32) 36 (41.9) 55 (50.9) * 1 (20) 92 (46.2) *
Class III AAD 6 (6.2) 42 (48.8) 55 (50.9) 2 (40) 99 (49.7) ***
Class IV AAD 3 (3.1) 4 (4.7) 7 (6.5) 5 (100) 11 (5.5)
Digoxin 0 (0) 6 (7) * 18 (16.7) *** 1 (20) 25 (12.6) ***
† The percentages of LVF are valid percentages and corrected for the missing values; ‡ Patients may use more than
one type of AAD; therefore, the sum of all classes is not equal to total; * p <0.05, ** p <0.01 and *** p <0.001 compared
to control ## p < 0.01 and ### p < 0.001 comparing paroxysmal AF with persistent AF.
3.2. Baseline HSP Levels Related to Clinical Stage of AF
To study the relationship between baseline HSP levels and the stage of AF, HSP27, HSP70,
cvHSP and HSP60 levels were determined in serum samples of PAF, PeAF and LSPeAF patients and
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compared to controls. Figure 1 shows baseline concentrations of serum HSP27, HSP70, cvHSP and
HSP60 of both control and AF patients; corresponding values are depicted in Supplemental Table S1.
These findings and the absence of a correlation between AF stage and HSP levels after correction for
potential confounders in a multivariate model (Supplemental Tables S2 and S3) indicate that there
are no differences in serum HSP values between the control patients and AF patients with PAF, PeAF
and LSPeAF.Cells 2020, 9, x 5 of 13 
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Figure 1. Baseline heat shock protein (HSP) serum levels in patients without and with (paroxysmal,
persistent and l t i t) atrial fibrillation (AF). HSP27 (A), HSP70 (B), cvHSP (C)
and HSP60 (D) expression evels (pg/mL) in baseline serum of control, paroxysm l atrial fibrillation
(PAF), p rsistent atrial fibrillation (PeAF), longstanding persistent atrial fibrillation (LSPeAF) and all
AF patients.
3.3. Relation between Baseline HSP Levels and AF Recurrence
In the total AF population, AF recurrence was significantly correlated to AF stage, age, dyslipidemia
and LVF, but not related to medication usage (Supplemental Table S4).
After ECV, AF recurrence was determined within 3 months (n = 52, 53.1%), 6 months (n = 55,
56.1%) and one year (n = 64, 65.3%) (Supplemental Table S5). Figure 2 shows the distribution of
the various HSP levels in patients with AF recurrence (red), compared to the remainder of the ECV
population (gr en). B seline HSP27, HSP70, cvHSP and HSP60 levels did not differ between patients
with or without AF recurrences within the first year after ECV (Figure 2, Supplemental Tables S5
and S6).
AF recurrences after PVI occurred within 3 months (n= 34, 34%), 6 months (n= 47, 47%) and within
1 year (n = 59, 58%) (Supplemental Table S7). For all time points, AF episodes were more often observed
in patients with P AF or LSPeAF, compared to patients with PAF (p < 0.01). Baseline serum HSP levels
did not discriminate between patients with and without AF recurrence, as demonstrated in Figure 3,
and Supplemental Table S6. However, HSP27 and HSP70 levels were significantly increased at 3-, 6- and
12-months post-PVI treatment in patients with an AF recurrence within one year, compared to baseline
levels (Figure 4 and Supplemental Table S6). The increase in serum HSP27 levels, and not HSP70
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levels, corrected for repeated measures, was significantly associated with AF recurrence (p < 0.013),
substantiating the role of HSP27 in the prediction of AF recurrence after PVI.Cells 2020, 9, x 7 of 13 
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Figure 4. HSP27 and HSP70 levels in follow-up serum were higher than baseline in patients having
AF recurrence. HSP27 serum levels (pg/mL) at baseline and at 3-, 6- and 12-months follow-up in
patients having AF recurrence within one year, compared to patients not having AF recurrence (A).
HSP70 serum levels (pg/mL) at baseline and at 3-, 6- and 12-months follow-up in patients having AF
recurrence within one year, compared to patients not having AF recurrence (B). # p < 0.05 and ## p < 0.01
compared to baseline serum HSP levels.
To relate HSP levels over time with AF recurrence as an endpoint, joint modeling was utilized.
Therefore, the occurrence of first AF recurrence (endpoint) in relation to the standardized (“Z”) value
of log2(HSP) was modeled, while using all measurements up to and including the moment of the
first AF recurrence in endpoint event cases, and all measurements in those who remained event-free.
The results are depicted in the Table 2 (row “all events”). One standard deviation (SD) difference in log2
HSP27 level was associated with a hazard ratio (HR) of 1.32 for having an AF recurrence, supporting
the outcomes from the repeated measure model Unfortunately, the joint modeling for HSP70 did not
converge, and therefore no reliable HR estimate could be obtained.
Table 2. Outcomes joint modeling of AF recurrence in relation to HSP levels, and sensitivity analyses.
Patients Samples HSP27 HSP70
AF AF-Free AF AF-Free HR 95%CILL
95%CI
UL p-Value HR
95%CI
LL
95%CI
UL p-Value
All events 59 41 114 99 1.32 1.71 1.54 <0.001 model does not converge
Complete
until 3 m 21 54 42 129 1.31 0.84 2.89 0.258 0.97 0.56 1.5 0.969
Complete
until 6 m 29 36 63 99 2.03 1.17 3.7 <0.001 1.03 0.54 1.97 0.926
Complet
until 12 m 31 13 70 34 model does not converge model does not converge
3.4. Sensitivity Analysis Non-Random Dropout
Although an association between HSP27 levels and the recurrence of AF after PVI was observed,
sensitivity analyses were conducted to evaluate the robustness of our findings in relation to possible
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non-random drop out. Therefore, joint models based on the following sensitivity datasets were run:
all available data (all events); patients with an AF recurrence at 3 months who also had an HSP
measurement at 3 months (21 cases), in combination with patients who were free of AF recurrence
at 3 months and with an HSP measurement ≥3 months (54 patients) (complete until 3 m); patients
with an AF recurrence at 3 or 6 months who also had an HSP measurement at the moment of the
AF recurrence (29 cases), in combination with patients who were free of AF recurrence at 6 months
and with an HSP measurement ≥6 months (36 patients) (complete until 6 m); and patients with an
AF recurrence at 3-, 6- or 12-months who also had an HSP measurement at the moment of the AF
recurrence (31 cases), in combination with patients who were free of AF recurrence at 12 months
and with an HSP measurement at 12 months (13 patients) (complete until 12 m). The findings of
the sensitivity analyses are provided in Table 2. HSP27 levels were associated with an HR of 2.03
for having an AF recurrence within 6 months post PVI treatment. The results confirm that HSP27 is
associated with AF recurrence, and may be used as a predictor. However, HSP70 does not seem to be
associated with AF recurrence.
4. Discussion
In this study, we observed that serum HSP27, HSP70, cvHSP and HSP60 levels in control patients
and patients with paroxysmal and (longstanding) persistent AF were comparable between the groups.
Thus, HSP27, HSP70, cvHSP or HSP60 levels could not discriminate between the different AF stages
in the total AF population. Additionally, at baseline, HSP27 and HSP70 serum levels were similar in
patients without and with AF recurrence within one year after treatment. However, both HSP27 and
HSP70 levels were higher at 3-, 6- and 12- months post-PVI compared to baseline levels in patients
with AF recurrence within one year. After joint modeling and sensitivity analyses, only increased
HSP27 levels post-PVI remained as a predictor of AF recurrence.
4.1. Heat Shock Proteins Are Not Biomarkers to Differentiate the Stage of Atrial Fibrillation
There is a great need for biomarkers to stage AF and to improve the selection of the proper
treatment for patients. Several (AF-related) serum biomarkers are routinely measured in clinical
practice, such as natriuretic peptide, troponin I, troponin T, creatinine and C-reactive protein [24–26],
but lack specificity for AF. Our findings indicate no role for HSP27, HSP70, cvHSP or HSP60 as a
biomarker for the presence or staging of AF. Our findings are in contrast to findings observed in other
studies, as reports revealed a correlation between serum HSP levels and AF. Hu et al. revealed an
association between baseline serum HSP27 levels and AF. In this study, serum HSP27 levels were
reduced in paroxysmal AF and (longstanding) persistent AF patients, compared to controls in normal
sinus rhythm [22]. Additionally, low serum HSP27 was associated with larger left atrial diameter,
low atrial voltage (indication of fibrosis [27]) and non-pulmonary ectopies. In addition, serum HSP27
could predict sinus rhythm maintenance and low serum HSP27 correlated with a higher AF recurrence
rate [22]. Our study could not confirm these findings. On the contrary, we observed an increase
in follow-up serum HSP27 and HSP70 levels in patients who developed AF recurrence post-PVI.
In addition, the increased HSP27 levels significantly correlate with AF recurrence. Despite this
interesting observation, due to the current study design we cannot determine whether the increase in
serum HSP levels is correlated with the duration of the AF episodes and whether this increase started
prior or post AF recurrence.
Serum HSP70 levels were similar in control and AF patients in our study and that of others [22,28].
In line with our study, no correlation between clinical or echocardiographic variables and serum
HSP70 levels was found and increased serum HSP70 levels at 6 months post-PVI correlated with AF
recurrence, substantiating our findings [28].
In patients who underwent CABG, baseline serum HSP70 levels were not predictive for
post-operative AF [29,30]. While no association between serum HSP60 level and occurrence of
AF was found by Maan et al. [31], Cao et al. [32] described that patients undergoing mitral valve
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replacement with AF had higher plasma HSP60 levels than patients in sinus rhythm. Higher plasma
HSP60 levels were also predictive for early (<7 days) post-operative AF [32]. Although not the protein
itself, pre- and post- operative circulating anti-HSP60 antibodies are associated with post-operative AF
in patients undergoing CABG [33]. In our study, serum HSP60, as well as cvHSP, did not discriminate
between the stage of AF or AF recurrence. The findings indicate that for baseline serum HSP27, HSP70,
cvHSP and HSP60 levels, no clear consensus exists for their use as a biomarker in AF.
4.2. Limitations and Future Directions: HSP in Relation to Degree of Electropathology
The current cross-sectional analysis provides information about whether HSP levels in serum
samples of AF patients differ from controls in sinus rhythm. To elucidate whether HSP levels predict AF
onset, detect early AF or detect progression of AF, a longitudinal study with repeated blood sampling
for HSP measurements and AF testing in subjects with normal sinus rhythm is required. Our control
serum HSP27 and HSP70 range is lower than the ranges described in other reports, which can be
explained by differences in the analytic assays used [22,29,30,34] and due to differences in disease
status of the various patient groups. The absence of difference in serum HSP levels between control
and AF patients may be attributed to the clinical nature of the control group.
It is generally accepted that AF is a multifactorial disease and predisposing conditions, e.g.,
diabetes mellitus, hypertension and higher age were omnipresent in all our study groups, including
the control group. It might be possible that the clinical variables we studied were too common and
we might need to search for more AF specific parameters, such as markers of structural damage that
are found to underlie atrial electrical conduction disorders, i.e., electropathology [35]. It has been
suggested that the clinical classification of AF, based on ECG measurements, as presented in the
guidelines, is inaccurate for AF staging because it is not related to the degree of atrial electropathology
as measured by high-resolution epicardial mapping [36]. Additionally, undiagnosed, silent and/or
very short-lasting AF episodes might have been overlooked in control patients and during follow-up
of ECV or PVI patients by using ECG measurements. As previous studies revealed exhaustion of HSP
levels in atrial tissue of persistent AF patients [18], in future research projects it is recommended to
investigate human HSP levels in both serum and atrial tissue and their relationship to parameters
related to AF-induced electrical and/or structural remodeling and also structural remodeling-induced
(post-operative) AF [37]. Thus, a lack of correlation between HSPs and AF stage in the current study
does not negate a role for HSPs as potential biomarker in AF. It is conceivable that serum HSP levels
correlate with the degree of electropathology. Future studies with continuous monitoring of electrical
parameters and HSP levels should elucidate such an association.
5. Conclusions
Serum HSP27, HSP70, cvHSP and HSP60 levels did not differentiate between AF stages and
controls in sinus rhythm. Moreover, AF recurrence after ECV or PVI was not associated with baseline
HSP levels. However, both HSP27 levels were increased during follow-up in patients with AF
recurrence after ablative therapy and may be used as predictors. Future research directed at elucidation
of an association between HSP levels and the degree of electropathology is recommended.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/9/2105/s1,
Table S1: Concentration of HSPs in serum at baseline of patients without AF and with (paroxysmal, persistent
or longstanding persistent) AF, Table S2: Univariate linear regression associations between clinical parameters
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